

AMENDMENT TRANSMITTAL LETTER			Docket No. 5108N1P1 (67326(54716))
Application No. 10/501,689	Filing Date July 17, 2004	Examiner T. A. Solola	Art Unit 1626

Applicant(s): Chengzhi Zhang et al.

Invention: BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TRATEMENT OF HYPER-PROLIFERATIVE DISORDERS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	26	- 26 =		x	
Independent Claims	4	- 4 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Extension for response within third month					1,020.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					1,020.00


- ☒ Large Entity ☐ Small Entity
- ☐ No additional fee is required for this amendment.
- ☒ Please charge Deposit Account No. 04-1105 in the amount of \$ 1,020.00.
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

William F. Gray, Ph.D., Esq.
Reg. No.: 31,018

Dated: April 25, 2007

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Phone (203) 812-2712

By:
Nicholas J. DiCeglie, Jr. (Reg. No. 51,615)
Attorney/Agent for the Applicants



Docket No.: 5108N1P1
(54716-67326)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chengzhi Zhang et al.

Application No.: 10/501,689

Confirmation No.: 4379

Filed: July 17, 2005

Art Unit: 1626

For: Benzofuran and Benzothiophene Derivatives
Useful in the Treatment of Hyper-
Proliferative Disorders

Examiner: T. Solola

AMENDMENT AND RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated October 26, 2006, please amend the above-identified U.S. patent application as described and consider the remarks presented herein. A three-month extension of time from January 26, 2007, to and including April 26, 2007, is submitted herewith.

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 10 of this paper.